vestronidase alfa-vjbk
| Brand name | Mepsevii |
|---|---|
| Active ingredient | vestronidase alfa-vjbk |
| Strength | 10MG/5ML (2MG/ML) |
| Dosage form | Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | November 2017 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.